Comparison of two micronized progesterones (Lutogel and Eutrogenic) in support of the luteal phase in patients undergoing IVF

Document Type : Original Article

Authors

1 Assistant Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Assistant Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Alborz University of Medical Sciences, Alborz, Iran.

Abstract

Introduction: Luteal phase support is an inevitable part of IVF programs, for this purpose, progestogenic therapies are used. Lutogel and Utrogestan are two progestogenic therapies that can be used as supportive drugs for the luteal phase. Utrogestan is a known drug to support the luteal phase. The aim of this study was to use Lutogel in case of effectiveness and tolerance as effective micronized progesterone to support the luteal phase in IVF patients due to the reduced availability in Iran.
Methods: This randomized clinical trial study (RCT) was performed on 200 patients referred to Infertility Clinic of Tehran Taleghani Hospital in 2019-2020. The subjects were divided into two equal groups and from the same day of getting oocyte one group was treated with 200 mg vaginal Lutogel and the other with 200 mg vaginal Utrogestan. Then the two groups were compared in terms of effectiveness, tolerability, safety, positive clinical pregnancy rate, successful pregnancy rate up to 12 weeks and abortion rates. Data were analyzed by SPSS statistical software (version 21) and Mann-Whitney, Chi-square and logistic tests. P <0.05 was considered statistically significant.
Results: Positive BHCG levels were 22% in Lutogel and 23% in Utrogestan groups that had no significant difference (P=0.866). Rate of pregnancy based on positive FHR in sonography was 18% in Lutogel and 22% in Utrogestan groups that no significant difference was found between the two groups (P=0.480). Rate of successful pregnancy up to 12 weeks was 13% for Lutogel and 15% for Utrogestan groups which showed not significant relationship between the two groups (P=0.684). The incidence of pregnancy more than 20 weeks was 14% in both Lutogel and Utrogestan groups, with no statistically significant difference (p=1.000).
Conclusion: The rate of positive BHCG, pregnancy based on positive FHR in sonography, and successful pregnancy up to 12 weeks were the same in the use of two Lutogel and Utrogestan drugs. Also, there was no difference in the incidence of complications. For this reason, each of these drugs can be used to support the luteal phase in patients undergoing IVF.

Keywords

References

  1. European IVF-monitoring Consortium (EIM), European Society of Human Reproduction and Embryology (ESHRE), Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, Erb K, Mocanu E, Motrenko T, Scaravelli G, Wyns C. Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Human Reproduction 2017; 32(10):1957-73.
  2. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends in Endocrinology & Metabolism 2003; 14(5):236-42.
  3. Toner JP. The luteal phase: luteal support protocols. In Gardner DK, Weissman A, Howles CM, eds. Textbook of assisted reproductive techniques. 2nd ed. London: Tailor & Francis; 2004. p. 639-650.
  4. Polyzos NP, Messini CI, Papanikolaou EG, Mauri D, Tzioras S, Badawy A, et al. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertility and sterility 2010; 94(6):2083-7.
  5. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Human Reproduction Update 2007; 13(6):581-90.
  6. Shapiro D, Boostanfar R, Silverberg K, Yanushpolsky EH. Examining the evidence: progesterone supplementation during fresh and frozen embryo transfer. Reproductive biomedicine online 2014; 29:S1-4.
  7. Hild-Petito S, Fazleabas AT. Expression of steroid receptors and steroidogenic enzymes in the baboon (Papio anubis) corpus luteum during the menstrual cycle and early pregnancy. The Journal of Clinical Endocrinology & Metabolism 1997; 82(3):955-62.
  8. Marinov B, Petkova S, Dukovski A, Georgiev G, Garnizov T, Manchev V, et al. Utrogestan and high risk pregnancy. Akusherstvo i ginekologiia 2004; 43(5):22-4.
  9. Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R, et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Human Reproduction 1999; 14(3):606-10.
  10. Check JH. Luteal phase support in assisted reproductive technology treatment: focus on endometrin®(progesterone) vaginal insert. Ther Clin Risk Manag 2009; 5:403-407.
  11. Michnova L, Dostál J, Kudela M, Hamal P, Langová K. Vaginal use of micronized progesterone for luteal support. A randomized study comparing Utrogestan® and Crinone® 8%. Biomedical Papers 2017.
  12. Child T, Leonard SA, Evans JS, Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reproductive biomedicine online 2018; 36(6):630-45.
  13. Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility and sterility 2017; 107(2):379-86.
  14. Shiba R, Kinutani M, Okano S, Kawano R, Kikkawa Y. Efficacy of four vaginal progesterones for luteal phase support in frozen‐thawed embryo transfer cycles: A randomized clinical trial. Reproductive medicine and biology 2020; 19(1):42-9.
  15. Khadem N, Mousavifar N, Bonakdar F, Baradaran Rafie N. A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI csycles. Iran J Obstet Gynecol Infertil 2011; 13(6):1-5.
  16. Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, et al. Endocrinology: Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction 1996; 11(10):2085-9.
  17. Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril 2007; 88(1):254-8.

The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 24, Issue 3
May 2021
Pages 16-22

Files

Share

How to cite

Statistics